Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $163.94 Average Price Target from Brokerages

Sarepta Therapeutics, Inc. (NASDAQ:SRPTGet Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the fourteen research firms that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $165.47.

SRPT has been the topic of a number of recent analyst reports. BMO Capital Markets assumed coverage on shares of Sarepta Therapeutics in a research report on Wednesday, January 31st. They issued an “outperform” rating and a $170.00 target price on the stock. Evercore ISI upped their target price on Sarepta Therapeutics from $108.00 to $138.00 and gave the company an “in-line” rating in a research report on Tuesday, February 20th. JPMorgan Chase & Co. cut their price target on Sarepta Therapeutics from $177.00 to $175.00 and set an “overweight” rating on the stock in a research report on Friday, May 3rd. TheStreet raised Sarepta Therapeutics from a “d” rating to a “c-” rating in a report on Monday, March 4th. Finally, Royal Bank of Canada upped their price target on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the company an “outperform” rating in a research report on Thursday, February 29th.

Check Out Our Latest Report on SRPT

Sarepta Therapeutics Trading Down 0.9 %

Shares of NASDAQ:SRPT opened at $127.13 on Tuesday. The company has a market cap of $12.02 billion, a PE ratio of 1,155.73 and a beta of 0.95. The company’s 50 day moving average is $127.02 and its two-hundred day moving average is $113.80. Sarepta Therapeutics has a 52 week low of $55.25 and a 52 week high of $146.68. The company has a current ratio of 4.05, a quick ratio of 3.44 and a debt-to-equity ratio of 1.18.

Sarepta Therapeutics (NASDAQ:SRPTGet Free Report) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.84. The business had revenue of $413.50 million during the quarter, compared to analysts’ expectations of $375.52 million. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The business’s quarterly revenue was up 63.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.44) EPS. Equities analysts predict that Sarepta Therapeutics will post 2.68 earnings per share for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 761 shares of the company’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $122.93, for a total transaction of $93,549.73. Following the transaction, the director now directly owns 7,516 shares in the company, valued at $923,941.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 761 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $122.93, for a total value of $93,549.73. Following the sale, the director now owns 7,516 shares of the company’s stock, valued at $923,941.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Bilal Arif sold 2,000 shares of the firm’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $128.84, for a total value of $257,680.00. Following the completion of the transaction, the insider now owns 26,836 shares of the company’s stock, valued at approximately $3,457,550.24. The disclosure for this sale can be found here. Insiders sold 25,731 shares of company stock worth $3,248,319 over the last 90 days. Company insiders own 7.70% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of SRPT. GAMMA Investing LLC raised its position in shares of Sarepta Therapeutics by 37.0% during the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 87 shares during the last quarter. Vanguard Capital Wealth Advisors increased its position in Sarepta Therapeutics by 3.8% during the fourth quarter. Vanguard Capital Wealth Advisors now owns 2,450 shares of the biotechnology company’s stock worth $236,000 after buying an additional 90 shares in the last quarter. Riggs Asset Managment Co. Inc. raised its holdings in shares of Sarepta Therapeutics by 125.0% in the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 125 shares during the last quarter. WCM Investment Management LLC raised its holdings in shares of Sarepta Therapeutics by 2.3% in the first quarter. WCM Investment Management LLC now owns 6,279 shares of the biotechnology company’s stock worth $813,000 after acquiring an additional 142 shares during the last quarter. Finally, Cary Street Partners Investment Advisory LLC lifted its position in shares of Sarepta Therapeutics by 154.0% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 154 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

(Get Free Report

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

See Also

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.